Cargando…
Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678745/ https://www.ncbi.nlm.nih.gov/pubmed/33274176 http://dx.doi.org/10.1155/2020/1939768 |
_version_ | 1783612219608530944 |
---|---|
author | Harrell, Carl Randall Jovicic, Biljana Popovska Djonov, Valentin Volarevic, Vladislav |
author_facet | Harrell, Carl Randall Jovicic, Biljana Popovska Djonov, Valentin Volarevic, Vladislav |
author_sort | Harrell, Carl Randall |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently needed. Due to their potent immuno- and angiomodulatory characteristics, mesenchymal stem cells (MSCs) may increase oxygen supply in the lungs and may efficiently alleviate ongoing lung inflammation, including SARS-CoV-2-induced ARDS. In this review article, we described molecular mechanisms that are responsible for MSC-based modulation of immune cells which play a pathogenic role in the development of SARS-CoV-2-induced ARDS and we provided a brief outline of already conducted and ongoing clinical studies that increase our understanding about the therapeutic potential of MSCs and their secretome in the therapy of COVID-19-related ARDS. |
format | Online Article Text |
id | pubmed-7678745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-76787452020-12-02 Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome Harrell, Carl Randall Jovicic, Biljana Popovska Djonov, Valentin Volarevic, Vladislav Anal Cell Pathol (Amst) Research Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently needed. Due to their potent immuno- and angiomodulatory characteristics, mesenchymal stem cells (MSCs) may increase oxygen supply in the lungs and may efficiently alleviate ongoing lung inflammation, including SARS-CoV-2-induced ARDS. In this review article, we described molecular mechanisms that are responsible for MSC-based modulation of immune cells which play a pathogenic role in the development of SARS-CoV-2-induced ARDS and we provided a brief outline of already conducted and ongoing clinical studies that increase our understanding about the therapeutic potential of MSCs and their secretome in the therapy of COVID-19-related ARDS. Hindawi 2020-11-20 /pmc/articles/PMC7678745/ /pubmed/33274176 http://dx.doi.org/10.1155/2020/1939768 Text en Copyright © 2020 Carl Randall Harrell et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Harrell, Carl Randall Jovicic, Biljana Popovska Djonov, Valentin Volarevic, Vladislav Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome |
title | Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome |
title_full | Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome |
title_fullStr | Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome |
title_full_unstemmed | Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome |
title_short | Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome |
title_sort | therapeutic potential of mesenchymal stem cells and their secretome in the treatment of sars-cov-2-induced acute respiratory distress syndrome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678745/ https://www.ncbi.nlm.nih.gov/pubmed/33274176 http://dx.doi.org/10.1155/2020/1939768 |
work_keys_str_mv | AT harrellcarlrandall therapeuticpotentialofmesenchymalstemcellsandtheirsecretomeinthetreatmentofsarscov2inducedacuterespiratorydistresssyndrome AT jovicicbiljanapopovska therapeuticpotentialofmesenchymalstemcellsandtheirsecretomeinthetreatmentofsarscov2inducedacuterespiratorydistresssyndrome AT djonovvalentin therapeuticpotentialofmesenchymalstemcellsandtheirsecretomeinthetreatmentofsarscov2inducedacuterespiratorydistresssyndrome AT volarevicvladislav therapeuticpotentialofmesenchymalstemcellsandtheirsecretomeinthetreatmentofsarscov2inducedacuterespiratorydistresssyndrome |